These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 20814331)

  • 1. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers.
    Novalbos J; López-Rodríguez R; Román M; Gallego-Sandín S; Ochoa D; Abad-Santos F
    J Clin Psychopharmacol; 2010 Oct; 30(5):504-11. PubMed ID: 20814331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
    Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
    Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
    Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.
    Kirchheiner J; Keulen JT; Bauer S; Roots I; Brockmöller J
    J Clin Psychopharmacol; 2008 Feb; 28(1):78-83. PubMed ID: 18204346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia.
    Locatelli I; Kastelic M; Koprivsek J; Kores-Plesnicar B; Mrhar A; Dolzan V; Grabnar I
    Eur J Pharm Sci; 2010 Oct; 41(2):289-98. PubMed ID: 20599499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers.
    Cabaleiro T; Ochoa D; López-Rodríguez R; Román M; Novalbos J; Ayuso C; Abad-Santos F
    Hum Psychopharmacol; 2014 Sep; 29(5):459-69. PubMed ID: 25042870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone.
    Kim KA; Park PW; Liu KH; Kim KB; Lee HJ; Shin JG; Park JY
    J Clin Pharmacol; 2008 Jan; 48(1):66-72. PubMed ID: 18094221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone].
    Ding JJ; Jiao Z; Yu YQ; Shi XJ
    Yao Xue Xue Bao; 2007 Jun; 42(6):631-8. PubMed ID: 17702401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition.
    Nakagami T; Yasui-Furukori N; Saito M; Tateishi T; Kaneo S
    Clin Pharmacol Ther; 2005 Jul; 78(1):43-51. PubMed ID: 16003291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.
    Yoo HD; Cho HY; Lee SN; Yoon H; Lee YB
    J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):329-41. PubMed ID: 22623266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
    Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
    Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
    Yagihashi T; Mizuno M; Chino B; Sato Y; Sakuma K; Takebayashi T; Takao T; Kosaki K
    Hum Psychopharmacol; 2009 Jun; 24(4):301-8. PubMed ID: 19387994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in CYP2D6 have a greater effect on variability of risperidone pharmacokinetics than gender.
    Cabaleiro T; Ochoa D; Román M; Moreno I; López-Rodríguez R; Novalbos J; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2015 Feb; 116(2):124-8. PubMed ID: 24975366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone.
    Hendset M; Molden E; Refsum H; Hermann M
    J Clin Psychopharmacol; 2009 Dec; 29(6):537-41. PubMed ID: 19910717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
    Leon Jd; Susce MT; Pan RM; Wedlund PJ; Orrego ML; Diaz FJ
    Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
    Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
    Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.
    Vandenberghe F; Guidi M; Choong E; von Gunten A; Conus P; Csajka C; Eap CB
    Clin Pharmacokinet; 2015 Dec; 54(12):1259-72. PubMed ID: 26129906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes.
    Ono S; Mihara K; Suzuki A; Kondo T; Yasui-Furukori N; Furukori H; de Vries R; Kaneko S
    Psychopharmacology (Berl); 2002 Jun; 162(1):50-4. PubMed ID: 12107617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.
    Zhang L; Brown SJ; Shan Y; Lee AM; Allen JD; Eum S; de Leon J; Bishop JR
    Pharmacotherapy; 2020 Jul; 40(7):632-647. PubMed ID: 32519344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.